

OK
7-10/20

a¹ wherein R is 5-methyl uracil (also referred to as thymine) and R' is hydrogen, acyl, alkyl, monophosphate, diphosphate, triphosphate, or a stabilized phosphate derivative or a pharmaceutically acceptable salt thereof.

12-16/23

mylon

Spec 26-28

Please add the following new claims:

a² 22. (new) The method of claim 2, wherein the compound is 2'-fluoro-5-methyl-β-L-arabinofuranosyl-uridine.

23. (new) The method of claim 22, wherein the compound is a pharmaceutically acceptable salt of 2'-fluoro-5-methyl-β-L-arabinofuranosyl-uridine.


Spec 23-28

17-19/18

24. (new) The method of claim 22, wherein the compound is a prodrug of 2'-fluoro-5-methyl-β-L-arabinofuranosyl-uridine.

25. (new) The method of claim 22, wherein the compound is administered in an enantiomerically enriched form.

26. (new) A method for the treatment of hepatitis delta infection comprising administering to a host an effective amount of a β-L nucleoside of the formula



32
wherein R is 5-methyl uracil (also referred to as thymine) and R' is hydrogen, acyl, alkyl, monophosphate, diphosphate, triphosphate, or a stabilized phosphate derivative or a pharmaceutically acceptable salt thereof, in combination or alternation with an effective amount of a compound selected from the group consisting of an interleukin; an interferon; an antibody to hepatitis B surface antigen or a transcriptional factor or other mediator of hepatitis B surface antigen expression; a protein-prenyl transferase inhibitor or thymosin-alpha-1.

514/12

27. (new) The method of claim 2, wherein the compound is at least 95% in its designated enantiomeric form.

28. (new) The method of claim 2, wherein the compound is administered in a pharmaceutically acceptable carrier.

29. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

30. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.

31. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

32. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.

33. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.

34. (new) The method of claim 28, wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

35. (new) The method of claim 28, wherein the compound is in the form of a dosage unit.

36. (new) The method of claim 28, wherein the dosage unit contains 10 to 1500 mg of the compound.

37. (new) The method of claim 35 or 36, wherein the dosage unit is a tablet or capsule.

REMARKS

Applicants cancel claims 1 and 3-21 and amend claim 2. New claims 22-37 have been added. The Examiner has restricted the prosecution to one of eight inventions under 35 U.S.C. § 121. Applicants elect Group I (claims 2-4) for further prosecution on the merits. The elected claims are drawn to methods of treating hepatitis delta infection comprising administering to a